Edwards Lifesciences shares moved higher in morning trading after the company reported better-than-expected results for the second quarter of 2026 and raised part of its outlook for the year.
The medical device maker reported adjusted earnings per share of $0.78 for Q2, above analysts' consensus of about $0.74, while total revenue reached $1.74 billion, up 12.5% year-over-year and higher than the roughly $1.70 billion analysts had forecast. Management also increased the low end of its full-year sales growth guidance to a range of 10% to 11%, setting expected total company sales between $6.6 billion and $6.9 billion for 2026.
Company commentary and segment performance
Management highlighted demand across its structural heart portfolio as the driver of the results. CEO Bernard Zovighian said growth was supported by "multiple therapies across TAVR, mitral, tricuspid, and surgical," and noted contributions from each geographic region.
Segment-level results underpinned the beat. TMTT sales jumped 44.8% year-over-year to $195.9 million, while TAVR revenue rose 10.5% to $1.3 billion. Both divisions exceeded Street expectations and helped propel the overall upside versus consensus.
Analyst reactions and insider activity
The quarter and guidance move prompted several brokerages to adjust their views. Leerink Partners upgraded the stock from Market Perform to Outperform and raised its price target to $101 from $87. Piper Sandler bumped its target to $101 from $100 while maintaining an Overweight rating. Bernstein raised its target to $99 from $96.
Insider transactions over the past six months have leaned toward sales. According to the company disclosure, that selling activity has not noticeably dampened market sentiment in light of the company's strong fundamental results.
Market context and trading behavior
The broader market provided a largely neutral backdrop: the S&P 500 inched up 0.1% and the Dow Jones added 0.2%, while the Nasdaq edged lower. There were no major macroeconomic releases or Federal Reserve announcements that materially affected trading, leaving Edwards Lifesciences' move driven principally by its corporate news.
The stock opened the day at $88.01, reached an intraday high of $89.08, and later pulled back to trade near $85.64, indicating some profit-taking after the initial post-earnings rally. The share price is trading comfortably above its 52-week low of $72.30 and remains in recovery toward its 52-week high of $96.29.
Taken together, the clean earnings beat, the guidance adjustment and several bullish analyst actions combined to lift investor sentiment around the company's outlook for continued demand across its structural heart therapies.